Tumor necrosis factor-alpha-induced interleukin-8 (IL-8) expression in endometriotic stromal cells, probably through nuclear factor-kappa B activation: gonadotropin-releasing hormone agonist treatment reduced IL-8 expression

Sakamoto Y, Yasuko Sakamoto, Harada T, Tasuku Harada, Sayako Horie, Horie S, Yumiko Iba, Iba Y, Fuminori Taniguchi, Taniguchi F, Souichi Yoshida, Yoshida S, Tomio Iwabe, Iwabe T, Terakawa N, Naoki Terakawa
The Journal of clinical endocrinology and metabolism · 2003 · vol. 88(2) , pp. 730–735 · doi:10.1210/jc.2002-020666 · PMID:12574206 · W2112165862
Lab / animal OA: bronze CC0 ⤵ 106 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-27 ⓘ

Tumor necrosis factor-α induces interleukin-8 expression in endometriotic stromal cells via nuclear factor-κB activation, and gonadotropin-releasing hormone agonist treatment reduces this expression by inhibiting NF-κB activation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis, a common disease among women of reproductive age, is characterized by the presence of endometrial-like tissue outside the uterus. We previously reported that TNFalpha promoted proliferation of endometriotic stromal cells by inducing IL-8 gene and protein expression. We hypothesize that TNFalpha may induce IL-8 production in endometriotic cells through nuclear factor-kappa B (NF-kappa B) activation. Western blot analyses and electrophoretic mobility shift assays revealed that incubation with TNF alpha induced the expression of phosphorylated inhibitor kappa B (p-I kappa B) and activation of NF-kappa B in endometriotic stromal cells. The NF-kappa B inhibitor, N-tosyl-L-phenylalanine chloromethyl ketone, reduced TNFalpha-induced IL-8 gene and protein expression. The medical treatment of endometriosis with GnRH agonist (GnRHa) has been shown to induce hypoestrogenemia and reduce the observable number of endometriotic implants. We compare the expression of IL-8 gene and protein in endometriotic stromal cells of patients treated with GnRHa and those of patients without treatment before laparoscopic cystectomy for endometrioma. The addition of TNFalpha (0.1 ng/ml) significantly increased protein and gene expression of IL-8 in the cells of patients without GnRHa treatment, but this expression was not observed in the cells of patients with GnRHa. The addition of estradiol (E2; 10(-7) M) enhanced the expression of IL-8. However, in the cells of patients who received GnRHa treatment, TNFalpha and E2 did not show any significant effect. In endometriotic stromal cells without GnRHa treatment, TNFalpha and E2 increased the expression of p-I kappa B. In contrast, TNFalpha and E2 had no significant effect on the expression of p-I kappa B in cells that received GnRHa treatment. These findings demonstrate that NF-kappa B activation is critical for TNFalpha-induced IL-8 expression in endometriotic stromal cells. The current study showed for the first time that GnRHa treatment attenuated the expression of IL-8 by reducing TNFalpha-induced NF-kappa B activation.

My notes (saved in your browser only)

Condition tags

endometriosisendometrioma

MeSH descriptors

Antineoplastic Agents Endometriosis Gonadotropin-Releasing Hormone Interleukin-8 NF-kappa B Tumor Necrosis Factor-alpha Adult Adult Antineoplastic Agents Antineoplastic Agents Cells, Cultured Cells, Cultured Electrophoretic Mobility Shift Assay Electrophoretic Mobility Shift Assay Endometriosis Endometriosis Endometriosis Endometriosis Estrogens Estrogens

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (22)

Cited by (50)

Source provenance

europepmc
last seen: 2026-10-15T06:08:49.021275+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:00:51.939714+00:00
License: CC0 · commercial use OK